RVPH News and Press, Reviva Pharmaceuticals Holdings Inc. From 11/20/23

CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...

2023-11-16 08:30:43 ET More on Reviva Pharmaceuticals Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER Reviva posts late-stage data for schizophrenia...

2023-11-16 08:25:47 ET Losers: Augmedix ( AUGX ) -25% announces proposed public offering of 5.5M shares of common stock. Velo3D ( VLD ) -18% on revising Q3 revenue lower , EPS drops to $0.09 Childrens Place ( PLCE ) -17% after Q3 earning relea...

CUPERTINO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...

2023-11-14 17:16:18 ET More on Reviva Pharmaceuticals Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER Reviva posts late-stage data for schizophrenia...

- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia – - Consistent Phase 3 RECOV...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Reviva Pharmaceuticals Holdings Inc. (RVPH) is expected to report $-0.35 for Q3 2023

2023-11-02 03:11:38 ET Summary Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo on the primary endpoint. The 15 mg dose of brilaroxazine was numerically superior to placebo on the p...

2023-10-31 08:17:59 ET Mersana Therapeutics  ( MRSN ) +21% Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056. Pinterest ( PINS ) +16% soars as Wall Street is impressed with turnaround strategy. Wolfspeed  ( WOLF ) +13%...